tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Oct 24;24(1):1197.
doi: 10.1186/s12879-024-10090-z. COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production
Takato Nakamoto[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 2 [/SUP], Yusuke Oshiro[SUP] 3 [/SUP], Natsumi Inamura[SUP] 3 [/SUP], Takashi Nemoto[SUP] 3 [/SUP], Satohi Ide[SUP] 2 [/SUP], Keiji Nakamura[SUP] 2 4 [/SUP], Hidetoshi Nomoto[SUP] 2 [/SUP], Yutaro Akiyama[SUP] 2 [/SUP], Tetsuya Suzuki[SUP] 2 [/SUP], Yusuke Miyazato[SUP] 2 [/SUP], Michiyo Suzuki[SUP] 2 [/SUP], Kumiko Suzuki[SUP] 5 [/SUP], Moto Kimura[SUP] 6 [/SUP], Sho Saito[SUP] 2 [/SUP], Satoshi Kutsuna[SUP] 2 7 [/SUP], Norio Ohmagari[SUP] 2 [/SUP]
Affiliations
Background: Dexamethasone is currently administered for Coronavirus disease 2019(COVID-19); however, there are concerns about its effect on specific antibodies' production. The aim of this study was to evaluate whether specific antibodies were affected by COVID-19 severity and corticosteroid treatment.
Methods: Of 251 confirmed COVID-19 patients admitted to our hospital between January 26 and August 10, 2020, the early period of the pandemic, 75 patients with sera within 1 month of onset and 1 month or longer were included in the research. A total of 253 serum samples from these patients were collected. The levels of specific antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), immunoglobulin G (IgG) and M (IgM), were measured retrospectively. The results were compared separately of each COVID-19 severity, and with or without corticosteroid treatment.
Results: Among the 75 patients, 47, 18, and 10 had mild, moderate, and severe disease, respectively. The median age was 53.0 years and 22 (29%) were women. The most common comorbidities were hypertension and dyslipidemia. Corticosteroids were administered to 20 (27%) and 10 (53%), patients with moderate and severe disease, respectively. The positivity rates IgM increased first, and IgG was almost always positive after day 16, regardless of the severity of COVID-19. On days 6-10, both IgG and IgM positivity rates were higher in patients with moderate disease than in those with mild or severe disease. In patients with moderate disease, IgG positivity was similar over time, regardless of corticosteroid treatment.
Conclusions: In COVID-19 patients, specific IgG is positive and maintained for a long period of time, even after corticosteroid treatment. The effect of corticosteroid treatment in a COVID-19 epidemiological study using specific IgG antibodies was considered minor. COVID-19 patients were more likely to receive oxygen if IgM was positive 1 week after onset, but not mechanical ventilation. IgM measurement 1 week after onset may predict COVID-19 severity.
Keywords: COVID-19; Corticosteroids; Severity; Specific antibody.
. 2024 Oct 24;24(1):1197.
doi: 10.1186/s12879-024-10090-z. COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production
Takato Nakamoto[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 2 [/SUP], Yusuke Oshiro[SUP] 3 [/SUP], Natsumi Inamura[SUP] 3 [/SUP], Takashi Nemoto[SUP] 3 [/SUP], Satohi Ide[SUP] 2 [/SUP], Keiji Nakamura[SUP] 2 4 [/SUP], Hidetoshi Nomoto[SUP] 2 [/SUP], Yutaro Akiyama[SUP] 2 [/SUP], Tetsuya Suzuki[SUP] 2 [/SUP], Yusuke Miyazato[SUP] 2 [/SUP], Michiyo Suzuki[SUP] 2 [/SUP], Kumiko Suzuki[SUP] 5 [/SUP], Moto Kimura[SUP] 6 [/SUP], Sho Saito[SUP] 2 [/SUP], Satoshi Kutsuna[SUP] 2 7 [/SUP], Norio Ohmagari[SUP] 2 [/SUP]
Affiliations
- PMID: 39443853
- DOI: 10.1186/s12879-024-10090-z
Background: Dexamethasone is currently administered for Coronavirus disease 2019(COVID-19); however, there are concerns about its effect on specific antibodies' production. The aim of this study was to evaluate whether specific antibodies were affected by COVID-19 severity and corticosteroid treatment.
Methods: Of 251 confirmed COVID-19 patients admitted to our hospital between January 26 and August 10, 2020, the early period of the pandemic, 75 patients with sera within 1 month of onset and 1 month or longer were included in the research. A total of 253 serum samples from these patients were collected. The levels of specific antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), immunoglobulin G (IgG) and M (IgM), were measured retrospectively. The results were compared separately of each COVID-19 severity, and with or without corticosteroid treatment.
Results: Among the 75 patients, 47, 18, and 10 had mild, moderate, and severe disease, respectively. The median age was 53.0 years and 22 (29%) were women. The most common comorbidities were hypertension and dyslipidemia. Corticosteroids were administered to 20 (27%) and 10 (53%), patients with moderate and severe disease, respectively. The positivity rates IgM increased first, and IgG was almost always positive after day 16, regardless of the severity of COVID-19. On days 6-10, both IgG and IgM positivity rates were higher in patients with moderate disease than in those with mild or severe disease. In patients with moderate disease, IgG positivity was similar over time, regardless of corticosteroid treatment.
Conclusions: In COVID-19 patients, specific IgG is positive and maintained for a long period of time, even after corticosteroid treatment. The effect of corticosteroid treatment in a COVID-19 epidemiological study using specific IgG antibodies was considered minor. COVID-19 patients were more likely to receive oxygen if IgM was positive 1 week after onset, but not mechanical ventilation. IgM measurement 1 week after onset may predict COVID-19 severity.
Keywords: COVID-19; Corticosteroids; Severity; Specific antibody.